Evaluate the Safety and Efficacy of Reslizumab for Patients With Eosinophilic Asthma

- Eosinophilic Asthma
- Terminated

Study Title: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Teva Identifier: C38072/3085 | 2010-024540-15

ClinicalTrials.gov Identifier: NCT01290887

Study Status: Terminated

Trial Condition(s): Eosinophilic Asthma

Interventions: Drug: Reslizumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Child, Adult, Older Adult

Age Range: 12 Years to 75 Years

Trial Duration: 06/01/2011 - 01/01/2015

Phase: Phase 3

Study Type

Interventional